| | |
Pertti Törmälä, Ph.D., M.D. Sci.h.c., B.M.S., Academy ProfessorPertti Törmälä, who is a board member and shareholder in Histola, has worked 30 years in medical device science and business developing first in the world for clinical use several bioabsorbable and bioactive implant families. Such implants have been e.g. bioabsorbable pins and screws for bone fracture fixation, arrows for fixation of knee meniscus ruptures and bioreplaceable small joint prostheses. Pertti Törmälä founded in 1984 the first successful company for manufacturing of bioabsorbable implants for tissue management. The company, Bionx Implants, was listed 1996 in Nasdaq stock market in New York. Törmälä is the chairman of the board and CSO in Bioretec, Ltd., which develops, manufactures and markets new generations of bioabsorbable and bioactive implants for musculoskeletal applications.
|
|
Hanna Tähti, Professor Emerita Hanna Tähti, Ph.D., prof. has a long experience in the field of toxicology, especially in the development of alternative methods for animal experimentation. She has done research in toxicology in the Medical School of the University of Tampere since 1973, and for some years she has also worked in pharmaceutical industry (Leiras, Tampere) as toxicologist. Together with Professor Timo Ylikomi she has established a Cell Research Centre in the Medical School at the University of Tampere in 1999. The role of the centre is to develop and validate new cell culture models for in vitro toxicology and for drug development. She has been leading research to develop methods for the safety evaluation of drugs and chemicals in vitro. The current research projects deal with developing an in vitro blood-brain barrier model for the evaluation of drug effects on the central nervous system, and a 3-dimensional model for the evaluation of the metabolism-induced toxicity in the target cells. She has been EUROTOX executive committee member 1997-2003, and she was one of the organizers (secretary general) of International Congress of Toxicology, ICT X 2004 in Tampere. She has been the chairman of Fincopa since its establishment (2003 in Tampere) until 2007, and still continues to be Fincopa board delegate.
|
|
Immo Rantala, Adj. Professor, PhDImmo Rantala, Medical Cell Biologist, Ph.D. is the chairman of the board and a shareholder of Histola Research Ltd. He has over 30 years experience in several areas of biomedical research and morphological diagnostics. Immo Rantala has worked as a laboratory chief in the Medical Faculty of Tampere University and in the Centre for Laboratory Medicine, Tampere University Hospital. At present he is the manager of Tissue Research Bank of Pirkanmaa
Hospital District. His special capabilities include immunology and morphologic techniques at both light and electron microscopic levels. In the introduction of immunomicroscopic methods such as immunohistochemistry and immunoelectron microscopy, he is a pioneer in Finland. Immo Rantala is still carrying out biomedical research, and he is mainly interested in kidney
diseases and in inflammatory bowel diseases.
Expertise: Management of scientific research projects, Development and adopting strategies of laboratory techniques, Management of laboratory business, Special areas of interest: tissue technologies, morphologic techniques, immunology
|
|
Heikki Kainulainen, ProfessorProfessor of exercise physiology, PhD, docent,
University of Jyväskylä, Finland
Research director, LIKES - Research Center for Sport and Health
Sciences
Jyväskylä, Finland
|
|
|
|
